Mike Brubaker

As the Chief Scientific Officer, Michael oversees all of Xequel Bio’s Research and Development, along with Regulatory Affairs. He helps drive the near and long-term strategy for Xequel, while proactively and strategically building partnerships with healthcare professionals and organizations to identify opportunities for joint value creation. Michael is committed to ensuring the scientific integrity of the R&D for Xequel.

Michael is a recognized pharmaceutical drug and medical device development expert with 25 years of experience with an emphasis in ophthalmic, otic, and respiratory disease areas. He has demonstrated sustained high performance throughout his career. Progressing from scientific/technical subject matter expert to technical and project management/leadership, strategic franchise leadership, project and portfolio management, and R&D executive leadership roles to current roles of global program leadership of drug development and medical device global development teams, he is a proven leader with ever increasing accountabilities and responsibilities.